{"news_desk": "Business", "print_page": null, "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By ROBERT CYRAN", "person": [{"rank": 1, "role": "reported", "firstname": "Robert", "organization": "", "lastname": "CYRAN"}]}, "abstract": null, "type_of_material": "News", "word_count": "386", "lead_paragraph": "The deal will bring hefty tax and cost savings worth slightly more than the $30 billion premium being offered, but the structure will upset lawmakers.", "pub_date": "2015-11-24T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Pfizer\u2019s Huge Deal Could Work, but With Adverse Effects", "content_kicker": "Breakingviews", "kicker": "Breakingviews"}, "snippet": "The deal will bring hefty tax and cost savings worth slightly more than the $30 billion premium being offered, but the structure will upset lawmakers.", "multimedia": [{"height": 126, "url": "images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 443, "url": "images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "443", "xlarge": "images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/11/24/business/dealbook/pfizers-huge-deal-could-work-but-with-adverse-effects.html", "keywords": [{"rank": "1", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "2", "is_major": "N", "value": "Federal Taxes (US)", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Allergan Inc", "name": "organizations"}, {"rank": "4", "is_major": "N", "value": "Pfizer Inc", "name": "organizations"}, {"rank": "5", "is_major": "N", "value": "Treasury Department", "name": "organizations"}, {"rank": "6", "is_major": "N", "value": "Read, Ian C", "name": "persons"}, {"rank": "7", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}], "blog": [], "_id": "5653313538f0d83c3238dc48", "source": "The New York Times"}